Position in ROIV
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$6,509
New position
Shares Held
235
first reported quarter
Ownership
0.000%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Position in Biotechnology
Healthcare · as of Mar 31, 2026Strive Financial Group ,LLC holds $158,557 across 9 Biotechnology names. ROIV ranks #6 (4.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
130 | $58,050 | |
| 2 | AXSM |
Axsome Therapeutics, Inc.
|
337 | $56,959 | |
| 3 | GNLX |
GENELUX Corp
|
5,000 | $12,100 | |
| 4 | CRSP |
CRISPR Therapeutics AG
|
230 | $10,941 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
10 | $7,726 | |
| 6 | ROIV |
Roivant Sciences Ltd.
This page
|
235 | $6,509 | |
| 7 | CNTX |
Context Therapeutics Inc.
|
1,700 | $4,454 | |
| 8 | VCEL |
Vericel Corp
|
36 | $1,158 |
All Filings in ROIV
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $6,509 | 235 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||